LUCIFERASE DIRECTED SUBSTRATES FOR CELL REGULATION

用于细胞调节的荧光素酶定向底物

• 批准号: 6486189
• 负责人: JOHN J NALEWAY
• 金额: $ 9.99万
• 依托单位: MARKER GENE TECHNOLOGIES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2003-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6486189
• 关键词: cell growth regulation; chemical synthesis; digital imaging; drug delivery systems; enzyme inhibitors; enzyme substrate; gene expression; genetic markers; immunoconjugates; luciferin monooxygenase; reagent /indicator; reporter genes; technology /technique development

DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new compounds capable of utilizing common marker gene expression in transformed cells to control the growth and character of cells in living tissue. If successful, the proposed research will provide breakthroughs needed to advance the promising medical uses of recombinant genes. In Phase I of this project, Marker Gene Technologies proposes to establish the feasibility of the technology by preparing new D-luciferin conjugates of common growth regulators, drugs and enzyme inhibitors, for administration to animal cells or bacteria that contain either the firefly luciferase gene (luc) as a gene fusion marker. These new conjugates will provide innovative methods of utilizing this reporter gene system in transformed cells to affect drug delivery and control selected biological properties. In Phase I, the new conjugates will be assayed in vitro and in vivo for their ability to cause specific and localized inhibition or improvement of cell growth and to deliver activated drugs in a cell- or tissue-specific manner, In Phase II, the conjugates will be further tested in a variety of significant medical applications.

描述（由申请人提供）：本小企业创新研究 第一阶段项目旨在研究开发新化合物的可行性 能够利用转化细胞中的共同标记基因表达， 控制活组织中细胞的生长和特性。如果成功， 拟议的研究将提供必要的突破，以推进有前途的 重组基因的医学用途。在该项目的第一阶段，标记基因 技术建议通过以下方式确定技术的可行性： 制备常见生长调节剂、药物和药物的新的D-精氨酸缀合物， 酶抑制剂，用于给予动物细胞或细菌，所述动物细胞或细菌含有 或者萤火虫荧光素酶基因（luc）作为基因融合标记。这些新 缀合物将提供利用该报告基因的创新方法 转化细胞中影响药物递送和控制选择的系统 生物学特性在第一阶段，新的结合物将在体外进行测定 以及在体内引起特异性和局部抑制的能力， 改善细胞生长和在细胞中递送活化的药物，或 在第II阶段，将以组织特异性方式进一步测试缀合物。 各种重要的医疗应用。